{
    "clinical_study": {
        "@rank": "154672", 
        "acronym": "PCV13", 
        "arm_group": {
            "arm_group_label": "PCV 13", 
            "arm_group_type": "Experimental", 
            "description": "Pneumococcal conjugate vaccine (PCV13, 0.5ml) 3 to 30 days prior to transplant and then again at 7-10 and 21-24 days after transplant"
        }, 
        "brief_summary": {
            "textblock": "There is no study hypothesis.  The purpose of this study is to see if the Pneumococcal\n      conjugate vaccine (PCV13), when administered before and early after an autologous peripheral\n      stem cell transplant will induce an immune response."
        }, 
        "brief_title": "Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a pilot study to determine the safety of PCV13 administered to patients with myeloma\n      before and at +7-10 days and +21-24 days after autologous hematopoietic stem cell\n      transplant; and,to quantify the immune response induced by PCV13 vaccination in patients\n      with myeloma when administered before and early after autologous PSCT."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients with confirmed multiple myeloma\n\n          -  eligible for treatment with high dose melphalan based regimen and autologous\n             peripheral stem cell transplant\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating woman, as evaluated by serum testing within 24 hours of\n             administration of the first vaccine\n\n          -  HIV infection confirmed by nucleic acid testing (NAT), as evaluated during pre\n             transplant testing\n\n          -  Common variable immunodeficiency or other inherited systemic immunodeficiency\n             syndrome\n\n          -  Active central nervous system (CNS) malignancy\n\n          -  Prior malignancy within 5 years of enrollment excluding non-melanoma skin cancer or\n             cervical carcinoma after curative resection, not requiring chemotherapy.\n\n          -  History of severe allergy (e.g., anaphylaxis) to any component of pneumococcal\n             conjugate vaccine 7 (PCV7), PCV13, or any diphtheria-toxoid containing vaccine.\n\n          -  Inclusion on a separate trial in which patients may be randomized or otherwise\n             started on maintenance chemotherapies within the first 3 months of autologous\n             transplantation\n\n          -  Patients with significant psychiatric illness likely to affect compliance, as\n             determined by the treating physician\n\n          -  Active or uncontrolled infection\n\n          -  Diffusing lung capacity oxygenation (DLCO) <50 %\n\n          -  Left ventricular ejection fraction (LVEF) <40%\n\n          -  Bilirubin >2"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01852591", 
            "org_study_id": "MCC-16727"
        }, 
        "intervention": {
            "arm_group_label": "PCV 13", 
            "intervention_name": "PCV13", 
            "intervention_type": "Biological", 
            "other_name": [
                "Prevnar", 
                "PCV13", 
                "pneumococcal conjugate vaccine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "autologous transplant", 
            "multiple myeloma"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "link": {
            "description": "H.Lee Moffitt Cancer Center & Research Institute", 
            "url": "http://www.moffitt.org"
        }, 
        "location": {
            "contact": {
                "email": "Frederick.Locke@moffitt.org", 
                "last_name": "Frederick L Locke, MD", 
                "phone": "813-745-7202"
            }, 
            "facility": {
                "address": {
                    "city": "Tampa", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33612"
                }, 
                "name": "H.Lee Moffitt Cancer Center & Research Institute"
            }, 
            "investigator": [
                {
                    "last_name": "Melissa Alsina, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jongphil Kim, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Bijal Shah, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Claudio Anasetti, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jose Ochoa-Bayona, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Taiga Nishihori, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Exploration of Immune Response to Pneumococcal Conjugate Vaccine (PCV13) Administered Before and Early After Autologous Peripheral Stem Cell Transplant (Auto-PSCT) in Patients With Multiple Myeloma", 
        "overall_contact": {
            "email": "Frederick.Locke@moffitt.org", 
            "last_name": "Frederick Locke, MD", 
            "phone": "813-745-7202"
        }, 
        "overall_official": {
            "affiliation": "H. Lee Moffitt Cancer Center and Research Institute", 
            "last_name": "Frederick L Locke, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Efficacy based on immunologic response pre/post-vaccination.", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "180 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01852591"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "H. Lee Moffitt Cancer Center and Research Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "H. Lee Moffitt Cancer Center and Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}